期刊
CLINICAL SCIENCE
卷 131, 期 5, 页码 395-409出版社
PORTLAND PRESS LTD
DOI: 10.1042/CS20160413
关键词
-
资金
- Ted Rogers Centre for Heart Research
- Canadian Institutes of Health Research
- FAMY, FAMY Norrbotten and Amyl
- Prothena Inc.
- Erik, Karin and Gosta Selander's Foundation
Transthyretin (TTR) amyloidosis (ATTR amyloidosis) is an underdiagnosed and important type of cardiomyopathy and/or polyneuropathy that requires increased awareness within the medical community. Raising awareness among clinicians about this type of neuropathy and lethal form of heart disease is critical for improving earlier diagnosis and the identification of patients for treatment. The following review summarizes current criteria used to diagnose both hereditary and wild-type ATTR (ATTRwt) amyloidosis, tools available to clinicians to improve diagnostic accuracy, available and newly developing therapeutics, as well as a brief biochemical and biophysical background of TTR amyloidogenesis.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据